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3-Amino-2-methyl-3H-quinazolin-4-one 1 reacts
with cyclic ketones 2a-d to afford the corresponding
cycloalkylidene-3-aminoquinazolinone derivatives 3a-d.
which on treatment reacted with mercaptoacetic acid to
give the spirothiazolidinones 4a-d. Also the reaction of
compounds 3a-d with chloroacetyl chloride in the pres-
ence of jriethylamine as a catalyst yield the respective
spiroazetidinones Sa-d. All the synthesized spirohetero-
cycle derivatives have been identified by conventional
methods IR and IH NMR spectroscopy and elemental
analyses.
Certain spiro compounds show anticancer 1, central
nervous system activity', antiinflammatory acti-
viti and antibiotic aranorosin". Recent literature
reports revealed the synthesis of spiroheterocycles
which were used as intermediates for aldose re-
ductase inhibitors'. Some new spiroheterocycles
are found to have activity as herbicides and pesti-
cides". Also, a facile access to aphidicolane and
stemodane B/CID-ring systems have been re-
ported?", and the syntheses of some new heterobi-
cyclic compounds containing the spiro-l ,2,4-
triazine moiety as potential anti HIV and antican-
cer agents were investigated" by us. The prepara-
tion of fluoran compounds for use as recording
materials has also been carried out'O-12.Also, the
preparation of spiroazafuranone derivatives to be
used for the treatment' of neurodegenerative disor-
ders and as anxiolytics were achieved':".
Quinazoline derivatives showed divers biological
activities'"!". Thiazolidinone derivatives have con-
siderable commercial importance as drugs e.g.
bactericidal, pesticidal, fungicidal, insecticidal,
anticonvulsant, tuberculostatic, antiinflammatory,
anti thyroidal and potentiation of pentobarbital in-
duced sleeping time":". Spirocycloalkylsubstituted
azetidinones were used as hypocholesterolemic
Note
agents". The syntheses of I3-lactams using differ-
ent techniques and catalysts have been accom-
plished":":", The syntheses of spiro compounds
containing nitrogen have gained importance be-
cause of their biological activity, but, in some
cases, the preparation of these compounds required
seven steps". Also, the preparation of the well-
known spiro derivatives, fredericamycin A, re-
quired eight steps". From all of the forgoing facts
it was very interesting to synthesize a new series of
spirothiazolidinones and spiroazetidinones incor-
porated with quinazoline. We report herein a facile
synthesis of some spiroquinazolineheterocycles
-derivatives analogous to spiro[indan-l, 1'[ IH]-3-
benzenepine] derivatives" and fredericamycin A26.
The advantages of our syntheses were the use of
inexpensive precursors such as anthranilic acid,
hydrazine hydrate, cyclic ketones and mercapto-
acetic acid, facile reactions, readily available rea-
gents and simple techniques. Our syntheses were
initiated with the reaction of 3-amino-2-methyl-
3H-quinazolin-4-one 1 with l-indanone 2a, 1-
tetralone 2b, fluorenone 2c and anthrone 2d to af-
ford the corresponding cycloalkylidene-3-
aminoquinazolinone derivatives 3a-d in good
yields (Scheme 1). The structure of compounds 3a-
d were established from their elemental analyses
and spectroscopic data (Table 1). The IR spectrum
of 3a showed characteristic strong absorption
bands at 1685 ern" corresponding to the stretching
vibrations of the carbonyl group of the quinazoline
ring and 1600 cm' for the C=N stretching. The 'a
NMR spectrum of 3a (DMSO-d6) showed the fol-
lowing signals: () 2.59 (2H, t) for the methylene
protons of the indan moiety, 3.05 (2H, t) for the
benzylic methylene protons of indan residue, 3.39
(3H, s) for the methyl protons at C2 of the
quinazoline ring and 7.00-8.14 ppm (8H, m) for
the aromatic protons of both quinazoline and indan
rings. The l3C NMR spectrum of 3a (DMSO-d6)
showed the following signals: () 21.88, 25.40,
35.83, 119.76, 122.84, 125.84, 126.60, 126.92,
127.06, 127.16, 133.82, 134.59, 136.64, 146.63,
155.20, 155.46, 160.08,206.24 ppm.












n R, Rz ~ R4
a 0 H H I ©(
b 1 H H ©(
c 0 ©( ©(




acid in dry benzene to give the target products (2H, t) for the methylene protons of the indan ring,
4a-d in good yields (Table 1, Scheme 1). The 2.59 (2H, t) for the benzylic methylene protons of
structures of compounds 4a-d were confirmed on the indan residue, 2.92 (2H, s) for the methylene
the basis of their elemental analyses and spectro- protons of thiazolidine ring, 3.40 (3H, s) for
scopic data (Table I). The 'H NMR spectrum of 4a methyl protons at C2 of quinazoline ring, 7.39-8.34
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quinazoline and indan rings. The \3C NMR spec-
trum of 4a (DMSO-d6) showed the following sig-
nals: 0 22.79, 27.84, 28.81, 119.67, 120.49,125.83,
126.42: 126.56, 128.29, 132.06, 133.82, 142.25,
144.60, 146.66, 152.85, 155.46, 155.79, 159.99,
174.67, 197.45. For the rigid identification of
compounds 4a-d, an unequivocal syntheses for
4a-d were established by the reaction of cyclic
ketones namely l-indanone 2a, l-tetralone 2b,
fluorenone 2c and anthrone 2d with mercaptoace-
tic acid in the presence of p-toluenesulfonic acid in
toluene to afford the spiroheterocyclic derivatives
6a-d in good yields" (Scheme II), which were sub-
sequently reacted with 3-amino-2-methyl-3H-
quinazolin-4-one 1 to afford the target compounds
4a-d. For the synthesis of the new spiroazetidinone
derivatives Sa-d, compounds. 3a-d reacted with
chloroacetyl chloride in benzene in the presence of
triethylamine as a catalyst to give the correspond-
ing spiroazetidinone derivatives 5a-d in good
yields (Scheme I). The structures of compounds
5a-d were elaborated on the basis of their elemen-
tal analyses and spectroscopic data (Table I). The
IR spectrum of compound Sa showed characteris-
tic strong absorption bands at 1730 cm', 1700 em"
corresponding to the stretching vibrations of the
carbonyl group of the azetidinone ring and the
quinazoline ring respectively, and at 790 em" for
C-Cl stretching vibration. The IH NMR spectrum
of Sa (DMSO-d6) showed the following signals: 0
2.43 (2H, t) for the methylene protons of the indan
moiety, 2.59 (2H, t) for the benzylic methylene
protons of the indan residue, 3.39 (3H, s) for
methyl at C2 of the quinazoline ring, 5.82 (IH, s)
the proton at C3 of the azetidinone ring, 7.00-8.4
ppm (8H, m) for the aromatic protons of the
quinazoline and indan rings. The \3C NMR spec-
trum of Sa (DMSO-d6) showed the. following sig-
nals: 022.60,25.84,28.81, 119.67, 120.49, 125.83,
126.2, 126.56, 128.29, 132.06, 133.82, 142.25,
144.60, 146.66, 152.85, 155.46, 155.79, 159.99,
174.67, 197.40 ppm.
Experimental Section
The time required for completion of each reac-
tion was monitored by TLC. Melting points are
uncorrected. IH NMR (8, ppm) spectra were meas-
ured on an EM-360 90-MHz spectrophotometer
using TMS as internal standard. A Varian FT-80 -
was used to obtain all 13CNMR (8, ppm) spectra.
IR (v, em") spectra were recorded on a Pye-
Unicam SP 200-G spectrophotometer. Elemental
analyses were determined on a Perkin-Elmer 240 C
microanalyser.
Synthesis of 3-amino-2-methyl-3B-quina-
zolln-s-one 1. This compound was prepared accor-
ding to the reported method".
Synthesis of cycloalkylidene-3-aminoquina-
zolin-4-one derivatives (3a-d): General Proce-
dure. Each compound 2a-d (0.01 mole) was fused
with compound 1 (0.01 mole) for 112 hr, then
25 mL of absolute ethanol was added to the reac-
tion mixture. The reaction mixture was refluxed
for 6 hr, cooled to room temperature whereby
compounds 3a-d were precipitated, filtered off and
dried. Yields, melting points and spectral analyses
are depicted in Table 1.
Synthesis of spirothiazolidinone derivatives
4a-d: General procedure. Each compound 3a-d
(0.001 mole) was dissolved in 25 mL of dry ben-
zene and to this solution, mercaptoacetic acid
(0.001 mole) was added. Then the reaction mixture
was refluxed for 8 hr. At the end of the refluxing
time, the solvent was removed by distillation and
the residue was poured into 50 mL of 20% sodium'
carbonate solution, whereby compounds 4a-d were
precipitated, filtered off and dried. The results are
given in Table 1.
Synthesis of spiroazetidinone derivatives
5a-d: General Procedure. Each compound 3a-d
(0.001 mole) was dissolved in 25 mL of dry ben-
zene and to this solution, chloroacetyl chloride
(0.001 mole) and triethylamine (0.001 mole) were
added. Then the reaction mixture was stirred at
room temperature for 10 hr. At the end of stirring
time, the solvent was removed by distillation and
the residue was poured into 25 mL of iced water,
whereby compounds 5a-d were precipitated, fil-
tered off and dried. Results are shown in Table 1.
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